These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23815861)

  • 1. Critical issue in the cardiovascular field: Hospitalization for heart failure.
    Sato N
    J Cardiol; 2013 Aug; 62(2):140-1. PubMed ID: 23815861
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic implications of treatment guidelines for congestive heart failure.
    Shibata MC; Nilsson C; Hervas-Malo M; Jacobs P; Tsuyuki RT
    Can J Cardiol; 2005 Dec; 21(14):1301-6. PubMed ID: 16341301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there any difference between angiotensin converting enzyme inhibitors and angiotensin receptor blockers for heart failure?
    Rain C; Rada G
    Medwave; 2015 Jul; 15 Suppl 1():e6177. PubMed ID: 26247213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
    Banka G; Heidenreich PA; Fonarow GC
    J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design.
    Fonarow GC; Abraham WT; Albert NM; Gattis WA; Gheorghiade M; Greenberg B; O'Connor CM; Yancy CW; Young J
    Am Heart J; 2004 Jul; 148(1):43-51. PubMed ID: 15215791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New studies influencing treatment of heart failure: 2006 update.
    Dunlap ME
    Pharmacotherapy; 2007 Apr; 27(4 Pt 2):3S-11S. PubMed ID: 17381369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibitor use in elderly patients hospitalized with heart failure and left ventricular systolic dysfunction.
    Rangaswamy C; Finn JI; Koelling TM
    Cardiology; 2005; 103(1):17-23. PubMed ID: 15528896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG; Cerulli A; Frech FH
    Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?
    Bangalore S; Kumar S; Messerli FH
    Congest Heart Fail; 2013; 19(3):107-15. PubMed ID: 23241032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From cost of illness to cost-effectiveness in heart failure.
    Lévy E
    Eur Heart J; 1998 Dec; 19 Suppl P():P2-4. PubMed ID: 9886705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart failure: epidemiology, economics and treatment.
    O'Connell JB; Moore CK
    J Miss State Med Assoc; 1996 May; 37(5):569-74. PubMed ID: 8709138
    [No Abstract]   [Full Text] [Related]  

  • 13. Are physicians failing CHF patients?
    Phillips L
    Hosp Technol Ser; 1997 Jun; 16(7):4-5. PubMed ID: 10169072
    [No Abstract]   [Full Text] [Related]  

  • 14. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
    Meune C; Wahbi K; Duboc D; Weber S
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality.
    Fonarow GC; Yancy CW; Hernandez AF; Peterson ED; Spertus JA; Heidenreich PA
    Am Heart J; 2011 Jun; 161(6):1024-30.e3. PubMed ID: 21641346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three year clinical review of the impact of angiotensin converting enzyme inhibitors on the intra hospital mortality of congestive heart failure in Nigerians.
    Adewole AD; Ikem RT; Adigun AQ; Akintomide AO; Balogun MO; Ajayi AA
    Cent Afr J Med; 1996 Aug; 42(8):253-5. PubMed ID: 8990572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease.
    Berger AK; Duval S; Manske C; Vazquez G; Barber C; Miller L; Luepker RV
    Am Heart J; 2007 Jun; 153(6):1064-73. PubMed ID: 17540211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after hospital discharge on subsequent rehospitalization for acute myocardial infarction and heart failure.
    Hess G; Preblick R; Hill J; Plauschinat CA; Yaskin J
    Congest Heart Fail; 2009; 15(4):170-5. PubMed ID: 19627290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective study of hospitalizations for heart failure in elderly patients in a cardiology service of a general hospital center].
    Zumer-Meulenbelt A; Joubert A; Lefort JF; Perchet H
    Arch Mal Coeur Vaiss; 2002 Sep; 95(9):769-74. PubMed ID: 12407790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology of acute heart failure].
    Montes-Santiago J; Arévalo Lorido JC; Cerqueiro González JM
    Med Clin (Barc); 2014 Mar; 142 Suppl 1():3-8. PubMed ID: 24930076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.